Sweden-based NorthX Biologics, which focuses on process development and large-scale production of advanced biological drugs, has signed a collaboration agreement with Abera Bioscience for upscaling and GMP manufacturing of its vaccine candidate against pneumococcus, Ab-01.12.   NorthX recently established an innovation hub to offer support to partners in achieving their long-term drug development goals. The company’s ability to handle new ways of working and experience with unique development ...